Compare Bill.com Holdings Inc (BILL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Crispr Therapeutics AG — how do they compare? Bill.com Holdings Inc trades at $49.15 (market cap $4.93B), while Crispr Therapeutics AG trades at $54.6 (market cap $5.23B). The key difference: Bill.com Holdings Inc and Crispr Therapeutics AG are close in size by market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BILL | CRSP | |
|---|---|---|
Market Cap | $4.93B | $5.23B |
Sector | Technology | Health |
52-Week High | $56.32 | $76.78 |
52-Week Low | $31.96 | $44.34 |
Enterprise Value | $4.64B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $49.26, up 2.65% today, showing strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth has accelerated from $642M in 2022 to $1.46B in 2025, with the company achieving positive net income for the first time. Recent leadership changes and operational efficiency initiatives, including a 30% workforce reduction, position the company for improved profitability.
The outlook remains positive with 56% analyst buy ratings and a consensus price target of $45.67, though current price exceeds this target. Key risks include high valuation multiples (P/E 213.91) and intense fintech competition. Upside catalysts include continued SMB adoption and AI-driven automation growth, while execution risks and market volatility present challenges for investors seeking exposure to the financial operations software sector.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
